Oxford Financial Group LTD. LLC Has $309,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Oxford Financial Group LTD. LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,590 shares of the company’s stock after selling 310 shares during the period. Oxford Financial Group LTD. LLC’s holdings in Novo Nordisk A/S were worth $309,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $28,000. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares during the period. Dunhill Financial LLC grew its position in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares in the last quarter. Albion Financial Group UT grew its stake in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after buying an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter valued at about $46,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 2.4 %

Shares of NYSE NVO opened at $76.88 on Friday. The company has a market cap of $344.98 billion, a PE ratio of 23.37, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm’s 50 day moving average price is $83.34 and its 200-day moving average price is $101.22. Novo Nordisk A/S has a 52-week low of $73.80 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Analyst Ratings Changes

Several analysts have weighed in on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.